Harrow Health (NASDAQ:HROW) Director Robert J. Kammer sold 6,500 shares of Harrow Health stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $5.25, for a total transaction of $34,125.00.

Shares of NASDAQ:HROW traded down $0.04 during trading on Wednesday, reaching $5.12. The stock had a trading volume of 3,199 shares, compared to its average volume of 265,207. Harrow Health has a 52 week low of $2.22 and a 52 week high of $8.99. The business’s 50-day moving average price is $5.52 and its 200 day moving average price is $5.97. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.87 and a quick ratio of 3.60. The stock has a market capitalization of $137.41 million, a PE ratio of 8.37 and a beta of 0.14.

Harrow Health (NASDAQ:HROW) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Harrow Health had a return on equity of 50.32% and a net margin of 51.32%. The company had revenue of $13.52 million during the quarter, compared to the consensus estimate of $12.55 million. Analysts forecast that Harrow Health will post -0.06 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Stone Ridge Asset Management LLC raised its position in Harrow Health by 35.2% in the 2nd quarter. Stone Ridge Asset Management LLC now owns 14,874 shares of the company’s stock worth $129,000 after purchasing an additional 3,874 shares during the last quarter. Vanguard Group Inc. raised its position in Harrow Health by 0.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,118,280 shares of the company’s stock worth $9,729,000 after purchasing an additional 9,112 shares during the last quarter. H D Vest Advisory Services bought a new position in Harrow Health in the 2nd quarter worth approximately $123,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Harrow Health in the 2nd quarter worth approximately $138,000. Finally, Wells Fargo & Company MN bought a new position in Harrow Health in the 2nd quarter worth approximately $158,000. Hedge funds and other institutional investors own 34.37% of the company’s stock.

A number of research firms have recently issued reports on HROW. Zacks Investment Research upgraded shares of Harrow Health from a “sell” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Friday, September 6th. Lake Street Capital set a $15.00 target price on shares of Harrow Health and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, ValuEngine upgraded shares of Harrow Health from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 11th.

About Harrow Health

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Recommended Story: Day Trading

Insider Buying and Selling by Quarter for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.